2023
Understanding Patterns of Missingness in Acute Ischemic Stroke Trials: A Secondary Analysis of Pooled Participant-Level Follow-Up Data
de Havenon A, Bangad A, Skolarus L, Aldridge C, Braun R, Cole J, Cramer S, Lindgren A, Sunmonu N, Worrall B, Lohse K. Understanding Patterns of Missingness in Acute Ischemic Stroke Trials: A Secondary Analysis of Pooled Participant-Level Follow-Up Data. Stroke 2023, 54: e201-e202. PMID: 36896708, PMCID: PMC10133020, DOI: 10.1161/strokeaha.122.042168.Peer-Reviewed Original ResearchConceptsAcute ischemic stroke trialsIschemic stroke trialsStroke trialsSecondary analysisFollowTrials
2022
Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial
Lang A, de Havenon A, Mac Grory B, Henninger N, Shu L, Furie K, Easton J, Kim A, Johnston S, Yaghi S. Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial. European Stroke Journal 2022, 8: 328-333. PMID: 37021190, PMCID: PMC10069178, DOI: 10.1177/23969873221148224.Peer-Reviewed Original ResearchConceptsSubsequent ischemic strokeEffect of clopidogrelSubsequent stroke riskIschemic strokeMajor hemorrhagePoint trialStroke riskSmoking statusMinor Ischemic Stroke (POINT) trialSubgroup interaction analysesMultivariable Cox regressionMinor ischemic strokeIschemic stroke trialsEffect of smokingNon-significant trendNew TIACurrent smokersStroke trialsTobacco smokingCox regressionIndex eventSmokersSecondary analysisClopidogrelStrokeSafety and efficacy of intensive systolic blood pressure lowering after successful endovascular therapy: a post hoc analysis of the BP TARGET trial
Anadani M, Maier B, Escalard S, Labreuche J, de Havenon A, Sabben C, Lapergue B, Mistry EA, Gory B, Spiotta AM, Richard S, Sibon I, Desilles JP, Blanc R, Piotin M, Mazighi M. Safety and efficacy of intensive systolic blood pressure lowering after successful endovascular therapy: a post hoc analysis of the BP TARGET trial. Journal Of NeuroInterventional Surgery 2022, 15: e142-e147. PMID: 36220337, DOI: 10.1136/jnis-2022-019130.Peer-Reviewed Original ResearchConceptsIntensive SBP treatmentHistory of hypertensionBlood pressure treatmentSuccessful endovascular therapyIntravenous thrombolysisLocation of occlusionEndovascular therapySBP treatmentAdmission SBPDiabetic patientsIntensive blood pressure loweringIntensive systolic blood pressureAcute ischemic stroke trialsTarget trialsEffect of SBPBlood pressure loweringNon-diabetic patientsFavorable functional outcomeSystolic blood pressureIschemic stroke trialsSite of occlusionIntensive SBPRecanalization statusSuccessful reperfusionBlood pressure
2021
Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial
de Havenon A, Johnston SC, Easton JD, Kim AS, Sheth KN, Lansberg M, Tirschwell D, Mistry E, Yaghi S. Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial. JAMA Network Open 2021, 4: e2112551. PMID: 34086033, PMCID: PMC8178708, DOI: 10.1001/jamanetworkopen.2021.12551.Peer-Reviewed Original ResearchConceptsBaseline systolic blood pressureDual antiplatelet therapySystolic blood pressureTransient ischemic attackMinor Ischemic Stroke (POINT) trialNew transient ischemic attackAcute ischemic strokeIschemic strokeIschemic stroke trialsStroke recurrenceHazard ratioBlood pressurePrimary outcomeStroke trialsElevated baseline systolic blood pressureFit Cox proportional hazards modelsHigher baseline systolic blood pressureElevated systolic blood pressureCox proportional hazards modelDays of randomizationFuture stroke riskIschemic stroke recurrenceUse of aspirinSubgroup of patientsProportional hazards model